Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | PKM | P14618 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | CDK2 | P24941 | 10/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PKLR | P30613 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652444 | 0.88 | CDK2 (0.74) | MEN1KMT2APKMLMNAMAPT | |
| SCHEMBL8222876 | 0.87 | PKM (0.72) | MEN1KMT2APKMLMNAMAPT | |
| SCHEMBL2243271 | 0.86 | MAPT (0.71) | MEN1KMT2APKMLMNAMAPT | |
| SCHEMBL2243629 | 0.84 | CDK2 (0.71) | MEN1KMT2APKMLMNAMAPT | |
| SCHEMBL2241359 | 0.83 | HTR2A (0.57) | MEN1KMT2APKMLMNAMAPT | |
| SCHEMBL4651601 | 0.83 | CDK2 (0.79) | MEN1KMT2APKMLMNAMAPT | |
| SCHEMBL18531434 | 0.82 | CDK2 (0.68) | MEN1KMT2APKMLMNAMAPT | |
| SCHEMBL18531470 | 0.81 | MAPT (0.64) | MEN1KMT2APKMLMNAMAPT | |
| SCHEMBL5579691 | 0.77 | KMT2A (0.63) | KMT2ACDK2 | |
| SCHEMBL5579686 | 0.77 | KMT2A (0.63) | KMT2ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086932-B1 | SUBSTITUTED ARYL-INDOLE COMPOUNDS AND THEIR KYNURENINE/KYNURAMINE-LIKE METABOLITES AS THERAPEUTIC AGENTS | NEURIM PHARMA 1991 (IL) | 2014-08-27 | — | — | EP | claimed |
| CN-101528689-B | Substituted aryl indole compounds and their kynurenine/kynuramine metabolites as therapeutic agents | NEURIM PHARMA 1991 | 2013-04-24 | — | — | CN | claimed |
| US-20100048663-A1 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2010-02-25 | — | — | US | claimed |
| US-7622495-B2 | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2009-11-24 | — | — | US | claimed |
| EP-2086932-B1 | SUBSTITUTED ARYL-INDOLE COMPOUNDS AND THEIR KYNURENINE/KYNURAMINE-LIKE METABOLITES AS THERAPEUTIC AGENTS | NEURIM PHARMA 1991 (IL) | 2014-08-27 | — | — | EP | disclosed |
| EP-2086932-B1 | SUBSTITUTED ARYL-INDOLE COMPOUNDS AND THEIR KYNURENINE/KYNURAMINE-LIKE METABOLITES AS THERAPEUTIC AGENTS | NEURIM PHARMA 1991 (IL) | 2014-08-27 | — | — | EP | disclosed |
| EP-2664615-A1 | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2013-11-20 | — | — | EP | disclosed |
| CN-101528689-B | Substituted aryl indole compounds and their kynurenine/kynuramine metabolites as therapeutic agents | NEURIM PHARMA 1991 | 2013-04-24 | — | — | CN | disclosed |
| US-8236858-B2 | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2012-08-07 | — | — | US | disclosed |
| US-8236858-B2 | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2012-08-07 | — | — | US | disclosed |
| US-8236858-B2 | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2012-08-07 | — | — | US | disclosed |
| US-20110319494-A1 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2011-12-29 | — | — | US | disclosed |
| US-7622495-B2 | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2009-11-24 | — | — | US | disclosed |
| US-7622495-B2 | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2009-11-24 | — | — | US | disclosed |
| CN-101528689-A | Substituted aryl indole compounds and their kynurenine/kynuramine metabolites as therapeutic agents | NEURIM PHARMA 1991 (IL) | 2009-09-09 | — | — | CN | disclosed |
| EP-2086932-A2 | SUBSTITUTED ARYL-INDOLE COMPOUNDS AND THEIR KYNURENINE/KYNURAMINE-LIKE METABOLITES AS THERAPEUTIC AGENTS | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2009-08-12 | — | — | EP | disclosed |
| US-20080132559-A1 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2008-06-05 | — | — | US | disclosed |
| US-20080132559-A1 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2008-06-05 | — | — | US | disclosed |
| US-20080132559-A1 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2008-06-05 | — | — | US | disclosed |
| WO-2008041140-A2 | SUBSTITUTED ARYL-INDOLE COMPOUNDS AND THEIR KYNURENINE/KYNURAMINE-LIKE METABOLITES AS THERAPEUTIC AGENTS | NEURIM PHARMACEUTICALS (1991) LTD. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132559-A1 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents | KYNU, KMO, GRIN1 | MEN1 4127/4885KMT2A 112/4885PKM 280/4885 |
| US-20100048663-A1 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents | KYNU, KMO, GRIN1 | MEN1 4127/4885KMT2A 112/4885PKM 280/4885 |
| US-20110319494-A1 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents | KYNU, KMO, GRIN1 | MEN1 4127/4885KMT2A 112/4885PKM 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.